Evidence map›Paper›PMID 22752857›Full record

Trial reportClinical infectious diseases : an official publication of the Infectious Diseases Society of America2012

Relapse versus reinfection: recurrent Clostridium difficile infection following treatment with fidaxomicin or vancomycin.

Iris Figueroa, Stuart Johnson, Susan P Sambol, Ellie J C Goldstein, Diane M Citron, Dale N Gerding

Abstract readClinical Trial, Phase IIIComparative StudyRandomized Controlled Trial
In one paragraph

Trial report in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 71 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
71citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

71 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Article
  8. Therapeutics involved in managing initial and recurrentWorld journal of gastrointestinal pharmacology and therapeutics · 2024
    Review
  9. Reduced Vancomycin Susceptibility in Clostridioides difficile Is Associated With Lower Rates of Initial Cure and Sustained Clinical Response.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2024
    Article
  10. Article
  11. Healthcare (Basel, Switzerland) · 2023
    Article
  12. Effect of the COVID-19 Pandemic on Rates and Epidemiology ofAntibiotics (Basel, Switzerland) · 2023
    Article
  13. Review
  14. Review
  15. ClostridioidesGastroenterology & hepatology · 2023
    Article
  16. Novel Biomarkers, IncludingInfection and immunity · 2023
    Article
  17. Article
  18. Article
  19. Fidaxomicin for the Treatment ofAntibiotics (Basel, Switzerland) · 2022
    Review
  20. Inhibition of In VitroMicroorganisms · 2022
    Article

11 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Iris FigueroaHines Veterans Affairs Hospital, Hines, IL 60141, USA.
Stuart Johnson
Susan P Sambol
Ellie J C Goldstein
Diane M Citron
Dale N Gerding

Funding

New Treatment for C. difficile-Associated DiarrheaR44AI063692 · NIAID · OPTIMER PHARMACEUTICALS, INC. · PI BABAKHANI, FARAH · 2007 to 2009
$3.0M
NIAID NIH HHS R44 AI063692
6 · The paper itself

Abstract

Our study sought to compare the strain types of Clostridium difficile causing initial and recurrent episodes of C. difficile infection (CDI) in adult patients with a first episode of CDI or 1 prior episode of CDI within the previous 90 days. Strains originated from patients who had been entered into two phase 3 randomized clinical trials of fidaxomicin versus vancomycin. Isolates of C. difficile from the initial and recurrent episodes within 28 (± 2) days of cure of CDI were compared using restriction endonuclease analysis (REA) typing. Paired isolates were available from 90 of 194 (46%) patients with recurrent CDI. Patients with isolates available were significantly younger (P = .008) and more likely to be from Canadian sites (P = .0001), compared with patients without isolates. In 75 of 90 subjects (83.3%), the identical REA type strain was identified at recurrence and the initial episode (putative relapse). Early recurrences (0-14 days after treatment completion) were relapses in 86.7% and a new strain (reinfection) in 13.3%. Later recurrences (15-31 days after treatment) were relapses in 76.7% and reinfections in 23.3%. Mean time (± standard deviation) to recurrence was 12.2 (± 6.4) days for relapses and 14.7 (± 6.8) days for reinfections (P = .177). The most common BI/NAP1/027 group and the previous US epidemic REA group J/NAP2/001 had a significantly higher combined rate of recurrence with the same strain (relapse), compared with the other REA groups (39 of 42 [93%] vs 36 of 48 [75%], respectively; P = .023). We found a higher than historic rate of recurrent CDI caused by the same isolate as the original episode, a finding that may be related to the relatively short observation period in this study and the high frequency of isolation of epidemic strains, such as groups BI and J, for which relapse rates may be higher than for other REA groups. Caution in generalizing these observations is required, because the patients studied were younger and more likely to be from Canadian sites than were patients with recurrence who did not provide isolates.

Indexed as

AdultAgedAminoglycosidesAnti-Bacterial AgentsBacterial ProteinsBacterial ToxinsBacterial Typing TechniquesCanadaClostridioides difficileClostridium InfectionsDiarrheaDNA, BacterialEnterotoxinsEuropeFecesFidaxomicinAminoglycosidesAnti-Bacterial AgentsBacterial ProteinsBacterial ToxinsDNA, BacterialEnterotoxinsFidaxomicinPHB2 protein, humanProhibitinstcdA protein, Clostridium difficiletoxB protein, Clostridium difficileVancomycin

Identifiers

PMID22752857
PMCPMC3388025

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.